Charles Benson

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

Medicine, Endocrinology, Pharmacology +17

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

Clemens Becker, Stephen R. Lord, Stephanie A. Studenski et al. · The Lancet Diabetes & Endocrinology · 2015 · 367 citations

Life Sciences, Geriatric Medicine, Immunology +8

A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

Robert R. Recker, Charles Benson, Toshio Matsumoto et al. · Journal of Bone and Mineral Research · 2014 · 291 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 276 citations · Full text

Medicine, Endocrinology, Pharmacology +17